Last updated: September 2, 2026
Penicillin G benzathine and penicillin G procaine are mature, low-cost injectable antibiotics with limited patent protection and high clinical importance. Their commercial economics are driven by manufacturing capacity, public-health demand, injectable supply chains, and regulatory quality requirements rather than branded pricing power. The main U.S. market exposure is Pfizer’s Bicillin L-A, a long-acting penicillin G benzathine product used primarily for syphilis and selected streptococcal infections. Penicillin G procaine has a smaller and less visible market, with availability varying by country and supplier.
What are penicillin G benzathine and penicillin G procaine used for?
Penicillin G benzathine and penicillin G procaine are depot formulations of penicillin G intended for intramuscular administration. They release active penicillin gradually, extending exposure compared with aqueous crystalline penicillin G.
| Product |
Active drug |
Formulation purpose |
Principal uses |
| Bicillin L-A |
Penicillin G benzathine |
Long-acting intramuscular suspension |
Syphilis, rheumatic fever prevention, selected streptococcal infections |
| Bicillin C-R |
Penicillin G benzathine plus penicillin G procaine |
Combined depot formulation |
Selected respiratory and skin infections where labeled |
| Procaine penicillin G |
Penicillin G procaine |
Intermediate-acting intramuscular suspension |
Certain bacterial infections, including syphilis in some jurisdictions |
Bicillin L-A is the preferred injectable treatment for most stages of syphilis when intramuscular penicillin is indicated. The Centers for Disease Control and Prevention recommends a single 2.4 million-unit dose for primary, secondary, and early latent syphilis in adults, with longer treatment for late latent disease and disease of unknown duration.[1]
The products are not interchangeable. Bicillin L-A contains benzathine penicillin G alone. Bicillin C-R contains both benzathine and procaine penicillin G. CDC has warned clinicians not to substitute Bicillin C-R for Bicillin L-A in syphilis treatment because the formulations have different pharmacokinetic and labeled-use profiles.[2]
How large is the penicillin G benzathine market?
The market is strategically important but financially modest relative to newer antibiotics and specialty drugs. Public revenue disclosures do not generally separate Bicillin L-A sales from Pfizer’s broader established medicines portfolio, and independent-market estimates vary by geography, formulation, and channel.
The U.S. market has several characteristics:
- Demand is concentrated in public-health programs, hospitals, clinics, sexually transmitted infection centers, and obstetric care.
- The number of suppliers is limited because sterile suspension manufacturing is technically demanding.
- Annual demand can change sharply with syphilis incidence, screening rates, pregnancy-related treatment, and public-health procurement.
- A shortage can create volume constraints even when underlying demand is stable.
- Price increases may occur during constrained supply, but low generic and public-sector pricing limits long-term margin expansion.
The commercial value of Bicillin L-A is therefore greater than its unit price suggests. The product is clinically difficult to replace for syphilis because oral alternatives are not equivalent in all patient groups, adherence is less certain, and penicillin remains the required treatment during pregnancy for preventing congenital syphilis.
What is driving demand for penicillin G benzathine?
Syphilis is the primary structural demand driver in the United States. CDC surveillance recorded a substantial increase in reported syphilis cases over the past decade, including rising congenital syphilis. Treatment demand has increased alongside case growth, prenatal screening, contact tracing, and public-health intervention.[3]
Syphilis and congenital syphilis
Pregnancy is an important demand segment because penicillin is the only documented effective therapy for preventing congenital syphilis. A shortage of injectable benzathine penicillin can therefore produce clinical and regulatory pressure even when the product is inexpensive.
Demand is also affected by:
- Repeat treatment for reinfection
- Treatment of sexual contacts
- Treatment of late latent syphilis
- Expanded screening among high-risk populations
- State and local health-department purchasing
- International shortages and allocation policies
Rheumatic fever prevention
Benzathine penicillin G is used for secondary prevention of rheumatic fever. This indication creates recurring demand in countries where rheumatic heart disease remains prevalent. The market is more dependent on public procurement and international health programs outside the United States.
Pediatric and streptococcal use
Bicillin L-A and related products are used for selected streptococcal infections when adherence to oral therapy is a concern. This segment is clinically relevant but generally smaller than the syphilis market.
What is the financial trajectory for Bicillin L-A?
The financial trajectory is best characterized as volume-constrained and supply-sensitive rather than innovation-driven.
Pfizer does not publicly report a standalone revenue line for Bicillin L-A. The product is part of Pfizer’s established medicines business, and public filings do not provide a reliable product-level revenue history. Financial analysis must therefore use market conditions, supply status, and portfolio disclosures rather than reported brand revenue.[4]
| Financial factor |
Effect on Bicillin L-A |
| Rising syphilis incidence |
Supports unit demand |
| Limited manufacturing capacity |
Restricts sales volume |
| Sterile injectable production |
Raises operating complexity |
| Generic-age active ingredient |
Limits pricing power |
| Public-health purchasing |
Creates concentrated buyer exposure |
| Shortage conditions |
Can support price increases but also reduce shipments |
| Lack of patent exclusivity |
Increases long-term competitive risk |
| Clinical necessity |
Supports durable demand and procurement priority |
The product may generate stable strategic value without producing high specialty-pharmaceutical margins. Its economics are supported by recurring demand and limited direct substitutes, but constrained by low unit pricing, government and hospital purchasing pressure, and the absence of meaningful patent-based exclusivity.
When does penicillin G benzathine lose exclusivity?
Penicillin G benzathine and penicillin G procaine are off-patent active ingredients. Their core chemical and therapeutic rights expired decades ago. Current commercial protection does not depend on a new-molecule patent term.
The relevant exclusivity structure is:
| Protection category |
Current commercial significance |
| Active-ingredient patent |
Expired |
| Core composition patent |
Expired or not commercially relevant |
| New-drug exclusivity |
Expired |
| Pediatric exclusivity |
Not a current market barrier |
| Orphan exclusivity |
Not applicable |
| Formulation patent |
Limited practical significance for the legacy products |
| Manufacturing know-how |
Material operational barrier |
| FDA approval and facility compliance |
Material regulatory barrier |
A legacy injectable can remain commercially defensible after patent expiry if few manufacturers can produce it reliably. In this market, sterile suspension formulation, particle-size control, filling, container compatibility, sterility assurance, and validated manufacturing processes may matter more than patent ownership.
What is the Orange Book status of Bicillin L-A?
Bicillin L-A is an FDA-approved prescription drug product with legacy new-drug application status. The FDA Orange Book is relevant for determining listed patents, reference-product status, and generic approval pathways, but it is not the principal source of commercial protection for this product.[5]
No current patent estate is widely recognized as creating a durable barrier to generic penicillin G benzathine entry comparable with modern branded medicines. Any Orange Book-listed patents, if present for a specific presentation or formulation, would need to be reviewed by product and FDA listing date. Their commercial value would also depend on whether an approved generic could satisfy the same injectable suspension, labeling, facility, and supply requirements.
For practical market analysis, the central barrier is supply reliability rather than patent expiry.
Are there Paragraph IV challenges to penicillin G benzathine?
Paragraph IV litigation risk appears limited compared with newer oral and specialty drugs. A generic applicant could challenge listed patents by certifying that a patent is invalid, unenforceable, or not infringed. The commercial incentive is weaker when:
- The reference product has low or uncertain revenue.
- Sterile injectable manufacturing requires substantial capital.
- The market has intermittent shortages but limited long-term pricing power.
- Procurement contracts favor established suppliers.
- Regulatory approval depends on complex suspension and manufacturing controls.
- The product has a narrow margin between commercial opportunity and supply-chain risk.
A Paragraph IV filing could still occur if a supplier identifies a profitable shortage opportunity. The more likely competitive pathway is a conventional abbreviated new drug application supported by formulation, bioequivalence, manufacturing, and labeling work rather than a major patent dispute.
What formulations are protected by patents or manufacturing know-how?
The most important technical issues concern depot suspension performance and sterile injectable manufacturing.
Penicillin G benzathine formulation barriers
A benzathine suspension must maintain consistent drug concentration, particle characteristics, syringeability, sterility, and release behavior. Relevant manufacturing controls include:
- Crystal and particle-size distribution
- Suspension uniformity
- Sedimentation and redispersibility
- Filling accuracy
- Container-closure integrity
- Sterility assurance
- Stability during refrigerated storage
- Compatibility with prefilled syringes and injection equipment
These controls can delay or prevent market entry even when the active ingredient is old. They are not equivalent to patent exclusivity. A competitor may overcome them through formulation development and process validation.
Penicillin G procaine formulation barriers
Procaine penicillin G has similar sterile-manufacturing requirements but generally has less commercial visibility in the United States. Its market is fragmented by country, presentation, indication, and procurement channel. Products may be marketed as generic injectables, combination products, or regionally approved formulations.
Which companies compete with Pfizer?
Pfizer has been the most visible branded supplier of Bicillin products in the United States. Competition outside the United States includes generic and regional manufacturers of benzathine penicillin G and procaine penicillin G.
The competitive landscape is fragmented:
| Competitor type |
Market position |
| Originator or legacy branded supplier |
Strong regulatory history and established distribution |
| Generic sterile-injectable manufacturer |
Potential price competition and supply diversification |
| Regional pharmaceutical company |
Important in government and emerging markets |
| Contract manufacturer |
May supply products under another company’s label |
| Public-sector procurement supplier |
Competes through tenders rather than brand strength |
The number of approved suppliers can be much lower than the number of companies with theoretical manufacturing capability. Regulatory approval, validated sterile facilities, raw-material quality, and procurement qualification determine actual competition.
What is the FDA regulatory status of Bicillin L-A and Bicillin C-R?
Bicillin L-A and Bicillin C-R are FDA-approved products. Their regulatory importance increased during U.S. supply shortages, when FDA and public-health agencies issued allocation and substitution guidance.
FDA shortage records have identified supply constraints affecting Bicillin L-A and, at different times, Bicillin C-R. The shortage environment has been influenced by demand growth, manufacturing capacity, and inventory distribution.[6]
Bicillin C-R is not a general substitute for Bicillin L-A in syphilis. CDC guidance has specifically addressed the risk of incorrect product selection, particularly because the names and packaging can appear similar.[2]
What patent litigation and settlement agreements affect these products?
There is no well-known, commercially decisive patent litigation or settlement framework comparable with major branded medicines such as HIV, oncology, or autoimmune products. The products are mature, and the principal competitive questions involve approval, manufacturing, procurement, and supply continuity.
Potential disputes are more likely to involve:
- Product quality
- Manufacturing compliance
- Contract supply
- Distribution allocation
- Product liability
- Regulatory classification
- Shortage-related purchasing
No major publicly documented settlement agreement is known to determine the current market structure for penicillin G benzathine or penicillin G procaine.
What generic launch risks exist for penicillin G benzathine?
A generic launch could reduce price but may not immediately increase available supply. The principal risks are operational.
Regulatory and technical risks
The applicant must demonstrate that the injectable product is equivalent in composition, strength, dosage form, route, and performance. The suspension’s physical properties and manufacturing process may require extensive development work.
Commercial risks
A new entrant faces:
- Small absolute market size relative to facility investment
- Low reimbursement and tender pricing
- Customer concentration
- Potential demand normalization after a shortage
- Expensive sterile-facility compliance
- Exposure to active-pharmaceutical-ingredient disruptions
- Difficulty securing predictable volume
Launch scenarios
| Scenario |
Market effect |
| No new reliable entrant |
Pfizer or incumbent suppliers retain supply leverage |
| One approved generic entrant |
Price pressure remains moderate; supply resilience improves |
| Multiple generic entrants |
Lower pricing and greater substitution risk |
| Continued syphilis growth with constrained supply |
Volume opportunity increases, but shortages persist |
| Demand normalization |
Excess capacity and weaker generic economics become risks |
A generic launch would be most valuable if it adds dependable manufacturing capacity rather than only lower list prices.
How does penicillin G procaine compare with penicillin G benzathine?
Penicillin G benzathine has the stronger commercial position in the United States because of its role in syphilis treatment and rheumatic fever prevention. Penicillin G procaine has a more limited and geographically variable market.
| Attribute |
Penicillin G benzathine |
Penicillin G procaine |
| U.S. commercial visibility |
Higher |
Lower |
| Syphilis role |
Standard injectable treatment in indicated cases |
Not interchangeable with benzathine product |
| Duration of action |
Longer depot exposure |
Intermediate depot exposure |
| Public-health importance |
High |
Moderate and region-specific |
| Brand concentration |
High in the U.S. |
More fragmented |
| Patent protection |
Legacy, expired |
Legacy, expired |
| Biosimilar exposure |
None |
None |
| Generic risk |
Moderate, constrained by sterile manufacturing |
Moderate, with smaller market economics |
Neither product faces biosimilar competition because both are small-molecule antibiotics, not biologics. Competition occurs through generic drug approval pathways.
What geographic markets matter most?
The United States is commercially important because of rising syphilis treatment demand and dependence on a limited number of injectable suppliers. Latin America, Asia, Africa, and parts of Eastern Europe have important public-health demand for benzathine penicillin G, particularly for syphilis and rheumatic heart disease.
International markets often depend on:
- Government tenders
- WHO procurement programs
- National essential-medicine lists
- Local registration requirements
- Regional manufacturing capacity
- Foreign-exchange availability
- Cold-chain and distribution infrastructure
The global market is therefore commercially fragmented. A manufacturer may have strong public-sector demand without achieving high margins.
How strong is the patent estate for penicillin G benzathine and procaine?
The patent estate is weak in the conventional sense. Core active-ingredient and therapeutic rights are long expired. The stronger barriers are operational and regulatory:
- Validated sterile manufacturing capacity
- Reliable supply of pharmaceutical-grade inputs
- Suspension formulation expertise
- FDA or local regulatory approval
- Procurement qualification
- Distribution continuity
- Clinical familiarity and institutional trust
This structure favors incumbent suppliers during shortages but does not create durable legal exclusivity. A well-capitalized generic manufacturer with an approved product and dependable supply could capture share.
Key Takeaways
- Penicillin G benzathine is the more commercially important product, driven by syphilis treatment and rheumatic fever prevention.
- Pfizer’s Bicillin L-A is strategically important, but standalone product revenue is not publicly disclosed.
- The products are long off-patent and have no meaningful new-molecule exclusivity.
- Orange Book and Paragraph IV issues are secondary to sterile manufacturing and regulatory execution.
- U.S. demand has increased because of rising syphilis and congenital syphilis cases.
- Supply shortages can create commercial opportunity but also expose manufacturers to production and allocation constraints.
- Penicillin G procaine has a smaller, more fragmented, and more geographically variable market.
- No biosimilar pathway applies; competition is through generic injectable approvals.
- The strongest barriers are manufacturing know-how, facility compliance, product quality, and procurement access.
- A successful generic entrant would need to provide reliable supply, not only a lower price.
FAQs
Is Bicillin L-A still under patent protection?
The active ingredient and core therapeutic rights are long expired. Any remaining product-specific listing would need to be evaluated in the FDA Orange Book, but patent protection is not the main commercial barrier.
Can Bicillin C-R be used instead of Bicillin L-A for syphilis?
No. CDC guidance states that Bicillin C-R should not be substituted for Bicillin L-A for syphilis treatment because the formulations differ.[2]
Does penicillin G benzathine have biosimilar competition?
No. Penicillin G benzathine is a small-molecule antibiotic. Potential competitors would use generic drug approval pathways rather than biosimilar pathways.
Why can an old antibiotic remain in shortage?
Sterile injectable production requires specialized facilities, validated suspension processes, quality controls, and reliable distribution. A mature product can remain supply-constrained even without patent protection.
Is penicillin G procaine commercially interchangeable with benzathine penicillin G?
No. The two formulations have different pharmacokinetic properties, clinical uses, and regulatory labeling. Substitution requires consideration of the approved product and treatment indication.
References
-
Centers for Disease Control and Prevention. (2021). Sexually transmitted infections treatment guidelines, 2021: Syphilis during pregnancy and treatment of syphilis. U.S. Department of Health and Human Services. https://www.cdc.gov/std/treatment-guidelines/syphilis.htm
-
Centers for Disease Control and Prevention. (2023). Shortage of benzathine penicillin G injectable suspension and guidance for alternative treatment. U.S. Department of Health and Human Services. https://www.cdc.gov/std/treatment-guidelines/
-
Centers for Disease Control and Prevention. (2024). Sexually transmitted infections surveillance 2022. U.S. Department of Health and Human Services. https://www.cdc.gov/sti-statistics/data-reports/
-
Pfizer Inc. (2024). Annual report 2023. https://www.pfizer.com/investors/financials/annual-reports
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2024). Drug shortages: Bicillin L-A and Bicillin C-R. https://www.accessdata.fda.gov/scripts/drugshortages/
